NCT05335005View on ClinicalTrials.gov

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

February 14, 2023

Study Completion Date

February 14, 2023

Conditions
End-Stage Renal DiseaseKidney Failure, Chronic
Interventions
DRUG

MK-2060

MK-2060 administered via IV infusion

Trial Locations (3)

33603

Genesis Clinical Research, LLC ( Site 0003), Tampa

9112001

Hadassah Medical Center-Clinical Reaserch Unit ( Site 0002), Jerusalem

010701

"ARENSIA Exploratory Medicine-Clinical Nephrology Hospital Carol Davila ( Site 0001)", Bucharest

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY